Literature DB >> 36245651

A Post Hoc Analysis of KidneyIntelX and Cardiorenal Outcomes in Diabetic Kidney Disease.

Girish N Nadkarni1,2, Dipti Takale3, Bruce Neal4, Kenneth W Mahaffey5, Yshai Yavin6, Michael K Hansen6, Fergus Fleming7, Hiddo J L Heerspink8, Steven G Coca2.   

Abstract

KidneyIntelX, a bioprognostic test for assessing risk of CKD progression, risk stratified individuals for kidney, heart failure, and death outcomes in the Canagliflozin Cardiovascular Assessment Study.Individuals scored as high risk seemed to derive more of benefit from treatment with canagliflozin versus placebo.These findings may serve to increase adoption of underutilized therapies for cardiorenal risk reduction in patients with diabetic kidney disease.
Copyright © 2022 by the American Society of Nephrology.

Entities:  

Keywords:  chronic renal disease; clinical nephrology; diabetes; diabetes mellitus; diabetic nephropathy

Mesh：

Substances：

Year:  2022        PMID： 36245651      PMCID： PMC9528375          DOI： 10.34067/KID.0002172022

Source DB:  PubMed          Journal:  Kidney360        ISSN： 2641-7650


  9 in total

1.  Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.

Authors:  Bruce Neal; Vlado Perkovic; Kenneth W Mahaffey; Dick de Zeeuw; Greg Fulcher; Ngozi Erondu; Wayne Shaw; Gordon Law; Mehul Desai; David R Matthews
Journal:  N Engl J Med       Date:  2017-06-12       Impact factor: 91.245

2.  Clinical Utility of KidneyIntelX in Early Stages of Diabetic Kidney Disease in the CANVAS Trial.

Authors:  David Lam; Girish N Nadkarni; Gohar Mosoyan; Bruce Neal; Kenneth W Mahaffey; Norman Rosenthal; Michael K Hansen; Hiddo J L Heerspink; Fergus Fleming; Steven G Coca
Journal:  Am J Nephrol       Date:  2022-01-11       Impact factor: 4.605

3.  SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.

Authors:  Brendon L Neuen; Tamara Young; Hiddo J L Heerspink; Bruce Neal; Vlado Perkovic; Laurent Billot; Kenneth W Mahaffey; David M Charytan; David C Wheeler; Clare Arnott; Severine Bompoint; Adeera Levin; Meg J Jardine
Journal:  Lancet Diabetes Endocrinol       Date:  2019-09-05       Impact factor: 32.069

4.  Relative and Absolute Risk Reductions in Cardiovascular and Kidney Outcomes With Canagliflozin Across KDIGO Risk Categories: Findings From the CANVAS Program.

Authors:  Brendon L Neuen; Toshiaki Ohkuma; Bruce Neal; David R Matthews; Dick de Zeeuw; Kenneth W Mahaffey; Greg Fulcher; Jaime Blais; Qiang Li; Meg J Jardine; Vlado Perkovic; David C Wheeler
Journal:  Am J Kidney Dis       Date:  2020-09-21       Impact factor: 8.860

Review 5.  Trajectories of kidney function in diabetes: a clinicopathological update.

Authors:  Megumi Oshima; Miho Shimizu; Masayuki Yamanouchi; Tadashi Toyama; Akinori Hara; Kengo Furuichi; Takashi Wada
Journal:  Nat Rev Nephrol       Date:  2021-08-06       Impact factor: 28.314

6.  Effects of SGLT2 inhibitors on cardiovascular and renal outcomes in type 2 diabetes: A meta-analysis with trial sequential analysis.

Authors:  Mei Qiu; Liangliang Ding; Hairong Zhou
Journal:  Medicine (Baltimore)       Date:  2021-03-12       Impact factor: 1.817

7.  Association of Race/Ethnicity, Gender, and Socioeconomic Status With Sodium-Glucose Cotransporter 2 Inhibitor Use Among Patients With Diabetes in the US.

Authors:  Lauren A Eberly; Lin Yang; Nwamaka D Eneanya; Utibe Essien; Howard Julien; Ashwin S Nathan; Sameed Ahmed M Khatana; Elias J Dayoub; Alexander C Fanaroff; Jay Giri; Peter W Groeneveld; Srinath Adusumalli
Journal:  JAMA Netw Open       Date:  2021-04-01

8.  Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial.

Authors:  Taha Sen; Jingwei Li; Brendon L Neuen; Bruce Neal; Clare Arnott; Chirag R Parikh; Steven G Coca; Vlado Perkovic; Kenneth W Mahaffey; Yshai Yavin; Norman Rosenthal; Michael K Hansen; Hiddo J L Heerspink
Journal:  Diabetologia       Date:  2021-08-20       Impact factor: 10.122

9.  Derivation and validation of a machine learning risk score using biomarker and electronic patient data to predict progression of diabetic kidney disease.

Authors:  Lili Chan; Girish N Nadkarni; Fergus Fleming; James R McCullough; Patricia Connolly; Gohar Mosoyan; Fadi El Salem; Michael W Kattan; Joseph A Vassalotti; Barbara Murphy; Michael J Donovan; Steven G Coca; Scott M Damrauer
Journal:  Diabetologia       Date:  2021-04-02       Impact factor: 10.122
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.